βPAK Inhibitors
βPAK, a member of the p21-activated kinase (PAK) family, plays a pivotal role in regulating various cellular processes, including cytoskeletal dynamics, cell motility, proliferation, and cell survival. As a serine/threonine kinase, βPAK acts downstream of small GTPases, such as Rac and Cdc42, which serve as molecular switches in signaling cascades regulating actin cytoskeleton remodeling and cell migration. βPAK exerts its effects by phosphorylating downstream substrates involved in cytoskeletal organization, cell adhesion, and cell cycle progression. Additionally, βPAK has been implicated in the regulation of cell polarity, neuronal development, and synaptic plasticity, highlighting its diverse functions in different cellular contexts. Dysregulation of βPAK activity has been associated with various diseases, including cancer, neurological disorders, and cardiovascular diseases, underscoring the importance of understanding its regulatory mechanisms and developing strategies for its inhibition.
Inhibiting βPAK activity represents a promising approach for targeting diseases associated with aberrant signaling pathways involving this kinase. Several mechanisms have been proposed for inhibiting βPAK function, including small molecule inhibitors that target the ATP-binding site of the kinase domain, preventing its phosphorylation activity. Additionally, allosteric inhibitors can disrupt the interaction between βPAK and its binding partners, thereby impairing its kinase activity and downstream signaling cascades. Furthermore, strategies aimed at inhibiting upstream regulators of βPAK, such as small GTPases or upstream kinases, can indirectly modulate βPAK activity and downstream cellular responses. Overall, elucidating the mechanisms of βPAK inhibition is essential for developing effective interventions targeting diseases driven by dysregulated βPAK signaling pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IPA 3 | 42521-82-4 | sc-204016 sc-204016A | 5 mg 50 mg | $94.00 $458.00 | 6 | |
A selective inhibitor of Group I PAKs (PAK1, 2, and 3). It binds non-catalytically to inhibit kinase activation, potentially inhibiting βPAK. | ||||||
PF-3758309 | 898044-15-0 | sc-478493 | 10 mg | $260.00 | ||
A potent and selective PAK inhibitor. It inhibits all PAK family members and could indirectly inhibit βPAK by targeting its kinase activity. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
A selective inhibitor of Cdc42-associated kinase (PAK1). By inhibiting PAK1, it could indirectly inhibit βPAK if it operates in the same pathway. | ||||||
AZD6482 | 1173900-33-8 | sc-364422 sc-364422A | 5 mg 10 mg | $275.00 $390.00 | 1 | |
A PI3Kβ inhibitor. Given the role of PI3K in regulating PAKs, this inhibitor might indirectly inhibit βPAK, especially if it is involved in PI3K-mediated signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A broad-spectrum kinase inhibitor with activity against Src family kinases. As Src kinases can regulate PAK activity, dasatinib might indirectly inhibit βPAK. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor. If βPAK is involved in pathways associated with Rho-kinase, Y-27632 could indirectly inhibit its activity. | ||||||
SL 0101-1 | 77307-50-7 | sc-204287 sc-204287A sc-204287B sc-204287C sc-204287D | 1 mg 10 mg 25 mg 50 mg 100 mg | $200.00 $353.00 $772.00 $1230.00 $2070.00 | 3 | |
Inhibits RSK (Ribosomal S6 Kinase), which is involved in the MAPK pathway. If βPAK is regulated by MAPK pathway components, this inhibitor could indirectly inhibit its activity. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
A classical PKC inhibitor. If βPAK is modulated by PKC-mediated pathways, Gö6976 might indirectly inhibit its activity. | ||||||